Drug Trial Radar · NCT04208529
A Long-term Follow-up Study in Participants Who Received CTX001
Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
160
Planned (sponsor's estimate)
Start
Jan 20, 2021
Primary completion
Sep 30, 2039
Study completion Sep 30, 2039
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- Collaborators
- CRISPR Therapeutics
- First posted
- Dec 23, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-site, open- label rollover study to evaluate the long-term safety and efficacy of CTX001 in pediatric and adult participants who received CTX001 in parent studies 111 (NCT03655678) 141 (NCT05356195) or 161 (NCT05477563) (transfusion-dependent β-thalassemia \[TDT\] studies) or Study 121 (NCT03745287) or 151 (NCT05329649) or 161(NCT05477563) (severe sickle cell disease \[SCD\] studies).
Conditions
- Beta-Thalassemia
- Thalassemia
- Sickle Cell Disease
- Hematologic Diseases
- Hemoglobinopathies
- Genetic Diseases, Inborn
- Sickle Cell Anemia
Interventions
CTX001Biological
CTX001 infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- New malignanciesTime frame: Signing of informed consent up to 15 years post CTX001 infusion
- New or worsening hematologic disordersTime frame: Signing of informed consent up to 15 years post CTX001 infusion
- All-cause mortalityTime frame: Signing of informed consent up to 15 years post CTX001 infusion
- Serious adverse events (SAEs)Time frame: Signing of informed consent up to 15 years post CTX001 infusion
- CTX001-related adverse events (AEs)Time frame: Signing of informed consent up to 15 years post CTX001 infusion
Locations
20 sites in 6 countries. Site status is shown where the registry gives one.
Lucile Packard Children's Hospital
Palo Alto, California
Ann & Robert H. Lurie Children's Hospital of Chicago - Hematology
Chicago, Illinois
Herbert Irving Pavilion - Hematology
New York, New York
New York Presbyterian Hospital - Morgan Stanley Children's Hospital
New York, New York
Levine Children's Hospital - Hematology
Charlotte, North Carolina
The Children's Hospital of Philadelphia - Hematology
Philadelphia, Pennsylvania
St. Jude Children's Research Hospital
Memphis, Tennessee
TriStar Medical Group Children's Specialists - Pediatric Oncology
Nashville, Tennessee
Methodist Healthcare System of San Antonio, Methodist Hospital, Methodist Children's Hospital
San Antonio, Texas
Hopital Universitaire des Enfants Reine Fabiola (HUDERF) - Hematology
Brussels, Belgium
Hospital for Sick Children - Hematology
Toronto, Canada
Toronto General Hospital - Hematology
Toronto, Canada
St. Paul's Hospital - Hematology
Vancouver, Canada
University Hospital Duesseldorf - Department of Pediatric Oncology, Hematology and Clinical Immunology
Düsseldorf, Germany
Center for Pediatric Clinical Studies (CPCS)
Klinik Für Kinder- Und Jugendmedizin, Germany
Regensburg University Hospital, Clinic and Polyclinic for Paediatric and Adolescent Medicine
Regensburg, Germany
IRCSS Ospedale Pediatrico Bambino Gesu - Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica
Rome, Italy
Great Ormond Street Hospital for Children
London, United Kingdom
Hammersmith Hospital - Haematology Dept
London, United Kingdom
University College London Hospital NHS Foundation - Main
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.